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Gone but Not Forgotten:  
Lesional Memory in Psoriatic Skin
Rachael A. Clark1
One of the most frustrating aspects of treating psoriasis is the tendency of pso-
riatic skin lesions to recur after therapy has been discontinued. Not only do 
lesions recur, but they often recur in the same anatomical locations, expanding 
to the size they were before therapy. This engenders feelings of frustration and 
futility in both patients and the dermatologists who care for them. In this issue, 
Suárez-Fariñas and colleagues identified a gene set—the residual disease genomic 
profile—of psoriasis, suggesting the presence of both immunologic and structural 
abnormalities within healed psoriatic lesions. By understanding this “invisible 
lesion,” we may be one step closer to curing psoriasis.
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Psoriatic skin lesions are a “riot” of dis-
order, featuring dense inflammatory cell 
infiltrates, massive proliferation, impaired 
differentiation of the epidermis, forma-
tion of new blood vessels, and alterations 
in lymphatic structure. With effective 
therapy, psoriatic lesions resolve without 
scarring. This lack of scarring is remark-
able, given the number of neutrophils 
in psoriatic skin lesions and the scarring 
observed in other neutrophil-mediated 
disorders, including pyoderma gangreno-
sum. Successful treatment of psoriasis 
leads to resolution of epidermal thick-
ness, reduced numbers of inflammatory 
cells, and return of previously affected 
skin to a clinically normal state (Chamian 
et al., 2005; Zaba et al., 2007).
Once therapy is discontinued, pso-
riatic skin lesions tend to recur, usually 
at the same sites that were affected pre-
viously. Clearly, something marks the 
boundary of healed psoriatic lesions 
that leads inflammation to recur in these 
places. Understanding and repairing the 
residual lesion in treated psoriatic skin 
may mean the difference between treat-
ing psoriasis and curing it.
In this issue, Suárez-Fariñas and co-
investigators address this important 
question. This group studied patients 
who had responded clinically and his-
tologically to therapy with the TNF-α 
antagonist etanercept. Previously lesion-
al but now normal-appearing skin was 
sampled, and three types of studies were 
performed. First, microarray and RT-PCR 
analyses were used to evaluate gene 
expression. The authors zeroed in on a 
set of previously identified psoriasis-asso-
ciated genes and determined which nor-
malized after therapy and which did not. 
A distinct set of genes remained abnor-
mally expressed in healed lesional skin. 
The authors refer to this gene set as the 
residual disease genomic profile of psori-
asis. These genes can be divided into two 
functional categories. Microarray studies 
demonstrated that a panel of inflamma-
tion-related genes remained elevated in 
treated lesions, including lymphotoxin 
and the T-cell receptor β1 chain. These 
two genes are both products unique to 
T cells, and their persistent elevation 
suggests the continued presence and 
activation of T cells in resolved lesions. 
RT-PCR studies confirmed elevated 
levels of IL-12p35, IL-22, IL-17, and 
IFN-γ, products of genes that are related 
to the presence and stimulation of IL-17–
producing T cells. A second set of genes 
with persistently abnormal expression 
mapped to structural cell types within the 
skin. These included genes expressed in 
lymphatic vessels and within the epider-
mis. Taken together, these studies suggest 
a continuing presence of both immuno-
logic and structural abnormalities within 
healed psoriatic lesions.
Suárez-Fariñas et al. (2011) then per-
formed a series of histologic studies to 
determine whether they could link gene 
expression alterations to observable 
changes within the skin. They found that 
a population of CD8+ T cells remained 
present in the dermis of treated lesions, 
a striking finding given the number of 
T-cell-related genes that remained abnor-
mally expressed. Second, they observed 
persistent changes in the morphology 
and gene expression of lymphatic vessels. 
Expression of the gene LYVE-1 was persis-
tently downregulated in healed psoriatic 
lesions as compared with normal skin. In 
normal skin, lymphatic channels express-
ing this gene were located in the upper 
reticular dermis and had wide, open 
lumens. In active and healed psoriatic 
lesions, these vessels were more collapsed 
and were located higher in the skin, 
closer to the dermal–epidermal junction. 
Although T cells and other inflamma-
tory cells use blood vessels to enter skin, 
they use lymphatic vessels to leave it. By 
restricting egress of inflammatory cells 
from skin, persistent lymphatic abnor-
malities could contribute to recurring 
inflammation. Abnormal lymphatics 
alone should not cause inflammation, 
but they may amplify and prolong inflam-
mation from other sources.
What then is the signature remain-
ing in resolved psoriatic lesions? As 
scientists, it is critical that we be aware 
of our own biases. The truth lies in the 
experimental findings themselves, not in 
the hypotheses we formulate to explain 
them. This is the cornerstone of good 
science and, indeed, good medicine. 
Admittedly, I think that most of the 
pathology in skin is caused by T cells. 
Despite this bias, the data do suggest 
that a persistent presence and activation 
of CD8+ T cells may mark the territory 
of psoriatic lesional skin and could be 
responsible for the recurrence of lesions 
in the same anatomical sites.
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One of the most significant ideo-
logical shifts in the field of cutaneous 
immunology has been the realization 
that effector T cells generated by local 
immune responses persist long-term 
within the skin and that they can pro-
vide protection against local rechallenge 
by pathogens (Clark, 2010; Gebhardt 
et al., 2009; Liu et al., 2010). At least a 
subset of these cells are sessile and non-
migratory, remaining fixed in location 
within the skin (Gebhardt et al., 2009). 
We as cutaneous immunologists have 
been peppered for years by insightful 
questions about why lesions of psoriasis, 
fixed drug eruption, and mycosis fungoi-
des recur at the same sites. It is possible 
that we are beginning to understand this 
phenomenon.
Mycosis fungoides is a form of 
cutan eous T-cell lymphoma in which 
malignant T cells are localized to fixed 
patches and plaques of inflamed skin. 
The lesions appear to resolve with topi-
cal steroid therapy but often recur in the 
same sites and regrow to their previous 
size. We have recently found that the 
malignant T cells in mycosis fungoides 
have the phenotype of effector memory 
T cells (TEM), a cell type that has been 
shown in mouse models to be nonmi-
gratory (Campbell et al., 2010). In con-
trast, the malignant T cells in Sézary 
syndrome have the phenotype of cuta-
neous central memory cells (TCM), a cell 
type that in mouse models recirculates 
among the skin, blood, and lymph 
nodes. It appears that these two forms 
of cutaneous T-cell lymphoma repre-
sent malignancies arising from two dif-
ferent T-cell subsets and that the malig-
nant T cells in these disorders maintain 
the migratory behaviors of their benign 
precursors. This would explain why 
patients with mycosis fungoides have 
fixed plaques that recur in the same 
locations and do not experience spread 
of malignant T cells into the blood or 
other tissues. It would also explain 
why patients with Sézary syndrome 
have erythroderma as opposed to fixed 
plaques (because the malignant T cells 
move within the skin), as well as accu-
mulation of malignant T cells in the 
blood and lymph nodes.
Fixed drug eruption is an unusual 
cutaneous hypersensitivity response in 
which patients develop dusky, usually 
solitary, plaques of inflamed skin. Once 
the offending drug is removed, the 
lesions resolve. If the offending medi-
cation is taken again, years or some-
times decades later, patients develop 
a recurrence of their skin lesions, often 
at the same anatomic sites affected 
previously. This is another example of 
a recurrent cutaneous reaction most 
likely caused by nonmigratory skin res-
ident T cells. Biopsy of resolved lesions 
of fixed drug eruption has demonstrat-
ed the continued presence of a distinct 
population of IFN-γ–producing CD8+ 
T cells (Teraki and Shiohara, 2003). 
These investigators did not demonstrate 
directly that these T cells were specific 
for the offending medication, but their 
findings suggest that nonmigratory 
CD8+ cells within these areas of skin 
are responsible for the fixed nature of 
this recurrent eruption.
Accumulating evidence suggests 
that psoriasis is an autoimmune T-cell–
mediated disorder, and recent studies 
have highlighted the importance of 
IL-17–producing T cells and activated 
dermal antigen-presenting cells in 
this process (Blauvelt, 2007; Lowes et 
al., 2007; Nickoloff, 2007). Because 
the dermis of healed psoriatic skin 
lesions is persistently colonized by a 
population of CD8+ T cells, it is pos-
sible that these lesion-resident CD8+ 
T cells may be the long sought-after 
autoreactive T-cell population in pso-
riasis. Indeed, CD8+ T cells producing 
IL-17 are found in psoriatic skin lesions 
but not in normal skin (Kryczek et al., 
2008). It is tempting to speculate that 
a nonmigratory population of auto-
reactive IL-17–producing CD8+ T cells 
is responsible for the fixed nature of 
psoriatic skin lesions and that the wax-
ing and waning activation state of these 
cells gives rise to the clinical variations 
in disease activity observed in patients.
It is possible, however, that structures 
distinct from T cells retain the memory 
of psoriatic lesions. Suárez-Fariñas 
et al. (2011) identify gene expression 
and morphologic changes in the lym-
phatic vessels of healed lesions that 
may exacerbate inflammation as a result 
of injury or other insults, leading to a 
low threshold for inflammation at the 
sites. They also identify changes in the 
gene expression of RAB31, a protein 
expressed by at least two populations of 
antigen-presenting cells in the skin. It is 
possible that psoriatic lesions are delin-
eated by nonmigratory antigen-present-
ing cells that, by persistent presentation 
of immunogenic self-peptides, stimulate 
autoreactive T cells and induce inflam-
mation selectively at these sites.
In summary, Suárez-Fariñas and 
colleagues (2011) have taken impor-
tant steps toward understanding the 
immunologic and structural footprint 
that remains after the clinically visible 
inflammation of psoriasis has passed. By 
understanding and treating these invis-
ible lesions, we may one day be able to 
give patients with psoriasis the gift they 
long for: truly normal skin.
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The coordinated Response of the 
Physical and Antimicrobial Peptide 
Barriers of the Skin
Andrew W. Borkowski1 and Richard L. Gallo1
Antimicrobial peptides (AMPs) are an essential and multifunctional element 
for immune defense of the skin during infection and injury. In this issue, 
Ahrens et al. characterize the response of β-defensins, a class of AMPs, fol-
lowing acute and chronic challenges to the permeability barrier of the skin. 
Their findings suggest that the antimicrobial and permeability barriers of the 
skin are closely linked.
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The multiple defensive functions of 
human skin depend on its ability to 
detect danger from a broad range of 
physical, chemical, and microbiologi-
cal challenges, and they are intercon-
nected to minimize the potential for 
damage. The skin’s defensive functions 
are often thought of as acting through 
two simultaneously acting barriers, 
the immune antimicrobial barrier 
and the physical permeability barrier. 
Following physical injury to the skin, 
a cascade of events occurs to restore 
the breached skin barrier and reestab-
lish homeostasis. In contrast, during 
infection, microbes encounter both 
the complex lipid and protein struc-
tures of the stratum corneum and an 
array of antimicrobial molecules that 
are already present or may be trig-
gered by a set of pattern recognition 
receptors. In combination, these barri-
ers typically act to facilitate the elimi-
nation of pathogens. In recent years, 
it has been shown that the pathways 
that generate and regulate the antimi-
crobial barrier of the skin are closely 
tied to pathways that modulate per-
meability barrier function (Dorschner 
et al., 2001; Schauber et al., 2007; 
Aberg et al., 2007, 2008). In this 
issue, Ahrens et al. report that both 
acute and chronic skin barrier disrup-
tion lead to increased expression of 
murine β-defensins (mBDs)-1, -3, and 
-14 and that this increase in expres-
sion is diminished when the barrier is 
artificially restored. Their data contrib-
ute to the concept that the antimicro-
bial and permeability barriers of the 
skin are closely linked.
antimicrobial nature of the skin
The integrity of the skin barrier is 
essential for it to properly serve its 
purpose as a shield from the environ-
ment. Keratinocytes are at the forefront 
of this defense because they make up 
the majority of epidermal cells and are 
in constant contact with the outside 
world. Keratinocytes are responsible 
for producing the stratum corneum, 
the terminally differentiated outer layer 
of the epidermis composed of rigid, 
anucleate corneocytes cemented by 
hydrophobic, lipid-rich lamellar bilay-
ers that impede water loss and protect 
from pathogenic organisms (reviewed 
in Candi et al., 2005). Although kera-
tinocytes serve as a physical barrier, 
they also express an array of mol-
ecules that contribute to the antimi-
crobial properties of skin (reviewed in 
Elias, 2007). A wide arsenal of weap-
ons combats possible invaders via the 
skin. Constant desquamation of the 
skin makes it difficult for organisms 
to establish permanent residence. The 
surface of the skin is an acidic envi-
ronment (pH ∼ 5.5) uninhabitable to 
many microorganisms. Additionally, it 
has been suggested that the microflora 
that normally inhabit human skin can 
contribute to barrier defenses by com-
peting for nutrients and niches that 
more pathogenic organisms require, 
by expressing antimicrobial molecules 
that kill or inhibit the growth of patho-
genic microbes (Cogen et al., 2010; 
Nakatsuji et al., 2010), and by modu-
lating the inflammatory response (Lai 
et al., 2009).
Over the past decade, it has become 
increasingly apparent that keratinocytes 
and other resident skin cells produce 
a number of antimicrobial molecules 
important for maintaining homeosta-
sis (Gallo and Huttner, 1998). Studies 
of antimicrobial peptides (AMPs) in 
many organ systems have shown them 
to engage in a wide range of activi-
ties including direct microbial killing, 
